OrbiMed’s Rocket Pharmaceuticals RCKT Stock Holding History

OrbiMed’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-253,108	Closed	-$5.79M	–	158
2020 Q3	$5.79M	Sell	253,108 -129,292	-34%	-$3.19M	0.07%	123
2020 Q2	$8M	Buy	+382,400	New	+$6.89M	0.11%	110
2018 Q4	–	Sell	-775,000	Closed	-$19.1M	–	147
2018 Q3	$19.1M	Hold	775,000	–	–	0.23%	92
2018 Q2	$15.2M	Hold	775,000	–	–	0.18%	102
2018 Q1	$14.5M	Buy	+775,000	New	+$12.6M	0.18%	93
2017 Q1	–	Sell	-462,325	Closed	-$11.3M	–	144
2016 Q4	$11.3M	Hold	462,325	–	–	0.14%	89
2016 Q3	$17.5M	Buy	462,325 +114,575	+33%	+$3.6M	0.2%	79
2016 Q2	$10.3M	Hold	347,750	–	–	0.11%	91
2016 Q1	$10.3M	Buy	347,750 +241,500	+227%	+$7.25M	0.11%	92
2015 Q4	$4.82M	Hold	106,250	–	–	0.04%	109
2015 Q3	$4M	Buy	+106,250	New	+$4.88M	0.04%	112

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

OrbiMed's RCKT Position: Q4 2020 in Review

OrbiMed sold out of Rocket Pharmaceuticals (RCKT) in Q4 2020, closing a stake of 253,108 shares — an estimated $5.79M sold.

OrbiMed first reported a position in RCKT in Q3 2015 and held it in 11 quarters. The position peaked at $19.1M in Q3 2018. 177 funds tracked by Wall St. Rank hold RCKT as of Q4 2020.

OrbiMed reported no remaining Rocket Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 253,108 Rocket Pharmaceuticals shares in Q4 2020, an estimated $5.79M.
OrbiMed first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 11 quarters.
OrbiMed's Rocket Pharmaceuticals position peaked at $19.1M in Q3 2018.
177 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.